PRESS-RELEASE ·Filed May 4, 2026
Press release · FDA
Actionable Insight • Neutral
Monitor for IND filing or partnership announcements. Given early-stage data, low probability of near-term stock movement; any upside would require positive clinical data or a collaboration deal.
Final — all horizons settled through T+60d ⚠ clustered
MCRB ▼ -39.53% at T+60d
NEUTRAL call -39.53% · α vs SPY -41.39% · entry $7.69 → $4.65
T+1d
-2.47%
call -2.47% · α -3.27%
$7.50
settled 6mo ago
T+5d
+1.95%
call +1.95% · α -0.99%
$7.84
settled 6mo ago
T+20d
-0.65%
call -0.65% · α -6.30%
$7.64
settled 5mo ago
T+60d
-39.53%
call -39.53% · α -41.39%
$4.65
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Seres Therapeutics presented preclinical data for SER-603, a next-generation live biotherapeutic for IBD, at DDW 2026. The data is early-stage (in vitro) and does not provide financial or regulatory catalysts, limiting near-term stock impact.
Key Facts
- SER-603 is a preclinical cultivated live biotherapeutic candidate for inflammatory bowel disease (IBD).
- Data presented at DDW 2026 was selected for 'Poster of Distinction' recognition.
- SER-603 is designed to modulate the GI microbiome, induce mucosal healing, and reduce inflammatory stimuli without immunosuppression.
- The company is advancing SER-603 through IND-enabling activities and seeking development partners.
Financial Impact
No financial data disclosed. No revenue or earnings impact at this preclinical stage.
Risk Factors
- Preclinical results may not translate to clinical efficacy.
- Company faces going concern risk and needs additional funding.
- SER-603 is early stage; clinical development timeline is years away.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286554 |
12 reports for MCRB
80% Hit rate @ T+20 Went positive at some point 4 of 5 best @ T+60▲ +36.27%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $1.98 | awaiting T+20 | — | $1.98 (−0.00%) |
Aug 24, 2026 9w ago | EFFECT | $4.66 $4.02 | ▲ +13.73% | ▲ +15.05% | $1.98 (+57.51%) |
Aug 5, 2026 11w ago | 8-K | $5.01 $5.54 | ▲ +10.69% | ▲ +11.29% | $1.98 (−60.44%) |
Jul 8, 2026 15w ago | 8-K | $7.14 $5.01 | ▼ −29.90% | ▼ −33.17% | $1.98 (−72.27%) |
Jun 5, 2026 20w ago | 8-K | $6.63 $7.71 | ▲ +16.29% | ▲ +14.43% | $1.98 (−70.14%) |
Jun 5, 2026 20w ago | Press Release | $6.63 $7.71 | ▲ +16.29% | ▲ +14.43% | $1.98 (−70.14%) |
May 19, 2026 22w ago | Insider Cluster | $7.66 $6.61 | ▼ −13.71% | ▼ −14.45% | $1.98 (−74.15%) |
May 5, 2026 25w ago | 8-K | $7.50 $7.33 | ▲ +2.27% | ▲ +7.22% | $1.98 (+73.60%) |
May 5, 2026 25w ago | Press Release | $7.50 $7.33 | ▲ +2.27% | ▲ +7.22% | $1.98 (+73.60%) |
May 4, 2026 25w ago | Press Release | $7.69 $7.64 | ▼ −0.65% | ▼ −6.30% | $1.98 (−74.25%) |
Showing 10 of 12
US Market Status
Market Closed — Opens in 23m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers